Knockdown of DEPTOR induces apoptosis, increases chemosensitivity to doxorubicin and suppresses autophagy in RPMI-8226 human multiple myeloma cells in vitro

International Journal of Molecular Medicine

Volumn 31, Issue 5, 2013, Pages 1127-1134

  Zhang, Haoran ^a   Chen, Junmin ^a   Zeng, Zhiyong ^a   Que, Wenzhong ^a   Zhou, Linying ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Autophagy; Deptor; Doxorubicin; Multiple Myeloma

Indexed keywords

BINDING PROTEIN; CASPASE 3; DANSYLCADAVERINE; DEPTOR PROTEIN; DOXORUBICIN; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; AUTOPHAGY; CELL PROLIFERATION; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; ENZYME ACTIVATION; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING;

APOPTOSIS; AUTOPHAGY; CELL LINE, TUMOR; CELL PROLIFERATION; DOXORUBICIN; GENE KNOCKDOWN TECHNIQUES; HUMANS; MULTIPLE MYELOMA; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84876111472     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2013.1299     Document Type: Article

References (49)

1. Kyle RA and Rajkumar SV: Multiple myeloma. N Engl J Med 351: 1860-1873, 2004.
2. Richardson PG, Mitsiades CS, Hideshima T and Anderson KC: Novel biological therapies for the treatment of multiple myeloma. Best Pract Res Clin Haematol 18: 619-634, 2005.
3. Dimopoulos MA, San-Miguel JF and Anderson KC: Emerging therapies for the treatment of relapsed or refractory multiple myeloma. Eur J Haematol 86: 1-15, 2011.
4. Duan S, Skaar JR, Kuchay S, et al: MTOR generates an auto-amplification loop by triggering the βTrCP-and CK1α-dependent degradation of DEPTOR. Mol Cell 44: 317-324, 2011.
5. Peterson TR, Laplante M, Thoreen CC, et al: DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 137: 873-886, 2009.
6. Zhao Y, Xiong X and Sun Y: DEPTOR, an mTOR inhibitor, is a physiological substrate of SCF(βTrCP) E3 ubiquitin ligase and regulates survival and autophagy. Mol Cell 44: 304-316, 2011.
7. Morgensztern D and McLeod HL: PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs 16: 797-803, 2005.
8. Hennessy BT, Smith DL, Ram PT, Lu Y and Mills GB: Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4: 988-1004, 2005.
9. Vivanco I and Sawyers CL: The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501, 2002.
10. Wullschleger S, Loewith R and Hall MN: TOR signaling in growth and metabolism. Cell 124: 471-484, 2006.
11. Edinger AL and Thompson CB: Defective autophagy leads to cancer. Cancer Cell 4: 422-424, 2003.
12. Gozuacik D and Kimchi A: Autophagy as a cell death and tumor suppressor mechanism. Oncogene 23: 2891-2906, 2004.
13. Maiuri MC, Zalckvar E, Kimchi A and Kroemer G: Self-eating and selfkilling: Crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol 8: 741-752, 2007.
14. Kim R, Emi M, Tanabe K, Murakami S, Uchida Y and Arihiro K: Regulation and interplay of apoptotic and non-apoptotic cell death. J Pathol 208: 319-326, 2006.
15. Thorburn A: Apoptosis and autophagy: Regulatory connections between two supposedly different processes. Apoptosis 13: 1-9, 2008.
16. Boya P, González-Polo RA, Casares N, et al: Inhibition of macroautophagy triggers apoptosis. Mol Cell Biol 25: 1025-1040, 2005.
17. Amaravadi RK, Yu D, Lum JJ, et al: Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest 117: 326-336, 2007.
18. Ravikumar B, Berger Z, Vacher C, O'Kane CJ and Rubinsztein DC: Rapamycin pre-treatment protects against apoptosis. Hum Mol Genet 15: 1209-1216, 2006.
19. Longo L, Platini F, Scardino A, Alabiso O, Vasapollo G and Tessitore L: Autophagy inhibition enhances anthocyanininduced apoptosis in hepatocellular carcinoma. Mol Cancer Ther 7: 2476-2485, 2008.
20. Herman-Antosiewicz A, Johnson DE and Singh SV: Sulforaphane causes autophagy to inhibit release of cytochrome c and apoptosis in human prostate cancer cells. Cancer Res 66: 5828-5835, 2006.
21. Bernstein E, Caudy AA, Hammond SM and Hannon GJ: Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 409: 363-366, 2001.
22. Zielske SP and Stevenson M: Importin 7 may be dispensable for human immunodeficiency virus type 1 and simian immunodeficiency virus infection of primary macrophages. J Virol 79: 11541-11546, 2005.
23. Pullmann R Jr, Juhaszova M, López de Silanes I, et al: Enhanced proliferation of cultured human vascular smooth muscle cells linked to increased function of RNA-binding protein HuR. J Biol Chem 280: 22819-22826, 2005.
24. Munafo DB and Colombo MI: A novel assay to study autophagy: Regulation of autophagosome vacuole size by amino acid deprivation. J Cell Sci 114: 3619-3629, 2001.
25. Mizushima M: Methods for monitoring autophagy. Int J Biochem Cell Biol 36: 2491-2502, 2004.
26. Klionsky DJ, Abeliovich H, Agostinis P, et al: Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy 4: 151-175, 2008.
27. Brummelkamp TR, Bernards R and Agami R: A system for stable expression of short interfering RNAs in mammalian cells. Science 296: 550-553, 2002.
28. Boyd KD, Walker BA, Wardell CP, et al: High expression levels of the mammalian target of rapamycin inhibitor DEPTOR are predictive of response to thalidomide in myeloma. Leuk Lymphoma 51: 2126-2129, 2010.
29. Hideshima T, Bradner JE, Wong J, et al: Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci USA 102: 8567-8572, 2005.
30. Pan Y, Gao Y, Chen L, et al: Targeting autophagy augments in vitro and in vivo antimyeloma activity of DNA-damaging chemotherapy. Clin Cancer Res 17: 3248-3258, 2011.
31. Kaufman SH: Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cell by etoposide, camptothecin and other cytotoxic anticancer drugs: A cautionary note. Cancer Res 49: 5870-5878, 1989.
32. Cheriyath V, Kuhns MA, Kalaycio ME and Borden EC: Potentiation of apoptosis by histone deacetylase inhibitors and doxorubicin combination: Cytoplasmic cathepsin B as a mediator of apoptosis in multiple myeloma. Br J Cancer 104: 957-967, 2011.
33. Carnero A, Blanco-Aparicio C, Renner O, Link W and Leal JF: The PTEN/PI3K/Akt signaling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets 8: 187-198, 2008.
34. Que W, Chen J, Chuang M and Jiang D: Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity. APMIS 120: 195-203, 2012.
35. McMillin DW, Ooi M, Delmore J, et al: Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. Cancer Res 69: 5835-5842, 2009.
36. de la Rubia J and Such E: DEPTOR expression and response to thalidomide: Toward a new therapeutic target in multiple myeloma? Leuk Lymphoma 51: 1960-1961, 2010.
37. Allan LA and Clarke PR: Apoptosis and autophagy: Regulation of caspase-9 by phosphorylation. FEBS J 276: 6063-6073, 2009.
38. Akiyama M, Hideshima T, Hayashi T, et al: Cytokines modulate telomerase activity in a human multiple myeloma cell line. Cancer Res 62: 3876-3882, 2002.
39. Cantley LC: The phosphoinositide 3-kinase pathway. Science 296: 1655-1657, 2002.
40. Brunet A, Bonni A, Zigmond MJ, et al: Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96: 857-868, 1999.
41. Datta SR, Brunet A and Greenberg ME: Cellular survival: A play in three Akts. Genes Dev 13: 2905-2927, 1999.
42. Kim D and Chung J: Akt: Versatile mediator of cell survival and beyond. J Biochem Mol Biol 35: 106-115, 2002.
43. Kang HY, Shim D, Kang SS, Chang SI and Kim HY: Protein kinase B inhibits endostatin-induced apoptosis in HUVECs. J Biochem Mol Biol 39: 97-104, 2006.
44. Han B, Wei W, Hua F, et al: Requirement for ERK activity in sodium selenite-induced apoptosis of acute promyelocytic leukemia-derived NB4 cells. J Biochem Mol Biol 40: 196-204, 2007.
45. Que WZ and Chen JM: Knockdown of c-Met inhibits cell proliferation and invasion and increases chemosensitivity to doxorubicin in human multiple myeloma U266 cells in vitro. Mol Med Rep 4: 343-349, 2011.
46. Knobloch J, Schmitz I, Götz K, Schulze-Osthoff K and Rüther U: Thalidomide induces limb anomalies by PTEN stabilization, Akt suppression, and stimulation of caspase-dependent cell death. Mol Cell Biol 28: 529-538, 2008.
47. Efeyan A and Sabatini DM: MTOR and cancer: Many loops in one pathway. Curr Opin Cell Biol 22: 169-176, 2010.
48. Zeng X and Kinsella TJ: Mammalian target of Rapamycin and S6 Kinase 1 positively regulate 6-thioguanine-induced autophagy. Cancer Res 68: 2384-2390, 2008.
49. Guertin DA and Sabatini DM: Defining the role of mTOR in cancer. Cancer Cell 12: 9-22, 2007.